BRPI0518299A2 - ciclopentanonas 2,3,4-substituÍdas como agentes terapÊuticos - Google Patents

ciclopentanonas 2,3,4-substituÍdas como agentes terapÊuticos

Info

Publication number
BRPI0518299A2
BRPI0518299A2 BRPI0518299-9A BRPI0518299A BRPI0518299A2 BR PI0518299 A2 BRPI0518299 A2 BR PI0518299A2 BR PI0518299 A BRPI0518299 A BR PI0518299A BR PI0518299 A2 BRPI0518299 A2 BR PI0518299A2
Authority
BR
Brazil
Prior art keywords
therapeutic agents
substituted cyclopentanones
cyclopentanones
substituted
disclosed
Prior art date
Application number
BRPI0518299-9A
Other languages
English (en)
Portuguese (pt)
Inventor
Yariv Donde
Mark Holobiski
Mari F Posner
Robert M Burk
Michael E Garst
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of BRPI0518299A2 publication Critical patent/BRPI0518299A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/52Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C07C405/0008Analogues having the carboxyl group in the side-chains replaced by other functional groups
    • C07C405/0033Analogues having the carboxyl group in the side-chains replaced by other functional groups containing sulfur
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/56Radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/06Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Detergent Compositions (AREA)
BRPI0518299-9A 2004-11-23 2005-11-21 ciclopentanonas 2,3,4-substituÍdas como agentes terapÊuticos BRPI0518299A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/997,039 US7183324B2 (en) 2004-11-23 2004-11-23 2,3,4-substituted cyclopentanones as therapeutic agents
PCT/US2005/042428 WO2006058063A1 (en) 2004-11-23 2005-11-21 2,3,4-substituted-cyclopentanones as therapeutic agents

Publications (1)

Publication Number Publication Date
BRPI0518299A2 true BRPI0518299A2 (pt) 2008-11-11

Family

ID=36087629

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0518299-9A BRPI0518299A2 (pt) 2004-11-23 2005-11-21 ciclopentanonas 2,3,4-substituÍdas como agentes terapÊuticos

Country Status (11)

Country Link
US (1) US7183324B2 (enExample)
EP (1) EP1814848B9 (enExample)
JP (1) JP5114205B2 (enExample)
AT (1) ATE475643T1 (enExample)
AU (1) AU2005309605B2 (enExample)
BR (1) BRPI0518299A2 (enExample)
CA (1) CA2588599A1 (enExample)
DE (1) DE602005022613D1 (enExample)
DK (1) DK1814848T3 (enExample)
ES (1) ES2347808T3 (enExample)
WO (1) WO2006058063A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7872045B2 (en) 2001-06-14 2011-01-18 Allergan, Inc. Combination therapy for glaucoma treatment
US20050222094A1 (en) * 2001-06-14 2005-10-06 Burk Robert M Treatment of inflammatory bowel disease
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
TWI386208B (zh) * 2005-04-18 2013-02-21 Allergan Inc 治療性的經取代環戊酮
US20070232660A1 (en) * 2006-04-04 2007-10-04 Allergan, Inc. Therapeutic and delivery methods of prostaglandin ep4 agonists
EP2147672A4 (en) 2007-05-08 2011-11-02 Nat University Corp Hamamatsu University School Of Medicine CYTOTOXIC T CELL ACTIVATOR WITH AN EP4 AGONIST
US7781465B2 (en) * 2007-08-21 2010-08-24 Allergan, Inc. Therapeutic oxazolidinones and thiazolidinones
US20110293549A1 (en) 2009-02-03 2011-12-01 Athena Cosmetics, Inc. Composition, method and kit for enhancing hair
JP2013508282A (ja) 2009-10-14 2013-03-07 ジェンムス ファーマ インコーポレイティド ウイルス感染のための併用療法処置
JP2013534251A (ja) * 2010-08-17 2013-09-02 アラーガン インコーポレイテッド 角膜混濁を治療するためのep2またはep4アゴニスト
AU2014305843B2 (en) 2013-08-09 2019-08-29 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
JP6482547B2 (ja) 2013-10-31 2019-03-13 アラーガン、インコーポレイテッドAllergan,Incorporated プロスタミド含有眼内インプラント及びそれらの使用方法
CN106928121B (zh) * 2015-12-29 2020-05-12 暨南大学 3-取代-苯并五元杂环-2-羰基化合物的高效制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
DE2715838A1 (de) 1977-04-05 1978-10-19 Schering Ag Neue prostanderivate und verfahren zu ihrer herstellung
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4131738A (en) 1977-07-05 1978-12-26 The Upjohn Company 6-Hydroxy-PGE1 compounds
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US6043275A (en) 1998-04-16 2000-03-28 Ono Pharmaceutical Co., Ltd. 3,7-dithiaprostanoic acid derivative
WO2000015608A1 (fr) 1998-09-14 2000-03-23 Ono Pharmaceutical Co., Ltd. Derives e de phenyl-prostaglandine a substitution-φ et medicaments les contenant comme ingredient actif
EP1339678B1 (en) 2000-11-27 2007-09-26 Pfizer Products Inc. Ep4 receptor selective agonists in the treatment of osteoporosis
US6410591B1 (en) 2001-05-08 2002-06-25 Allergan Sales, Inc. 3,7 or 3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure
US20030027853A1 (en) 2001-06-14 2003-02-06 Allergan Sales, Inc. 3, 7or3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure
CA2450466C (en) 2001-06-14 2011-07-05 Allergan, Inc. 3, 7 or 3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure
US7101906B2 (en) * 2004-11-16 2006-09-05 Allergan, Inc. 2,3,4-substituted cyclopentanones as therapeutic agents

Also Published As

Publication number Publication date
ES2347808T3 (es) 2010-11-04
EP1814848A1 (en) 2007-08-08
EP1814848B9 (en) 2011-12-21
DK1814848T3 (da) 2010-11-08
JP2008520737A (ja) 2008-06-19
AU2005309605B2 (en) 2012-08-23
WO2006058063A1 (en) 2006-06-01
US7183324B2 (en) 2007-02-27
US20060111430A1 (en) 2006-05-25
AU2005309605A1 (en) 2006-06-01
JP5114205B2 (ja) 2013-01-09
CA2588599A1 (en) 2006-06-01
ATE475643T1 (de) 2010-08-15
ES2347808T9 (es) 2011-06-13
EP1814848B1 (en) 2010-07-28
DE602005022613D1 (en) 2010-09-09

Similar Documents

Publication Publication Date Title
TW200714583A (en) Substituted gamma lactams as therapeutic agents
ATE377589T1 (de) 6-substituierte nikotinamidderivate als opioidrezeptorantagonisten
DE602004024375D1 (de) Carboxamidderivate
SE0401345D0 (sv) Therapeutic compounds: Pyridine as scaffold
CR10327A (es) "PIRIDIN(3-4-b) PIRAZINONAS"
UY30500A1 (es) Compuestos de azabencimidazolilo
ATE406360T1 (de) Antagonisten der opioidrezeptoren
SE0401971D0 (sv) Piperidne derivatives
ATE506340T1 (de) 12-aryl-prostaglandin-analoga
WO2008008660A3 (en) Cyclopentane derivatives as antiglaucoma agents
SE0401342D0 (sv) Therapeutic compounds
EA200801083A1 (ru) Новые производные дигидропсевдоэритромицина
BRPI0518299A2 (pt) ciclopentanonas 2,3,4-substituÍdas como agentes terapÊuticos
WO2008008718A3 (en) Cyclopentane derivatives as antiglaucoma agents
DK2173749T3 (da) 2-oxo-2-(2-phenyl-5,6,7,8-tetrahydro-indolizin-3-yl)-acetamidderivater og beslægtede forbindelser som antisvampemidler
ECSP088829A (es) Derivados de bencimidazol 5-sulfonamida como ligandos del receptor cannabinoide 1 (cb1)
DE60302157D1 (de) Opioidrezeptorantagonisten
BRPI0716643A2 (pt) amidas terapêuticas e compostos relacionados
MX2010004487A (es) Derivados lactamicos sustituidos y sus usos para glaucoma e hipertension ocular.
WO2007146856A3 (en) Substituted gamma lactams as therapeutic agents
DE602005021150D1 (de) 3-substituierte pyridinderivate als h3-antagonisten
DE602005010744D1 (de) Piperazinylpyridinderivate als mittel gegen adipositas
WO2008094912A3 (en) Substituted gamma lactams as therapeutic agents
WO2007130890A3 (en) Cyclopentane-derivatives and their use as ocular hypotensive agents
TW200719901A (en) Therapeutic substituted cyclopentanones

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]